Predictors of poor function in RA based on two prospective UK inception cohorts. Do comorbidities matter?

**Rheumatology* 2021; DOI:10.1093/rheumatology/keab598

Innovative trial approaches in immune-mediated inflammatory diseases: Current use and future potential

*BMC Rheumatology* 2021; 5:21

Developing a predictive signature for two trial endpoints using the cross-validated risk scores method

*Biostatistics* 2021; DOI: 10.1093/biostatistics/kxaa055

Revisiting the JOQUER trial: Stratification of primary Sjögren's syndrome and the clinical and interferon response to hydroxychloroquine

*Rheumatology International* 2021; 41(9):1593-1600

A review of Bayesian perspectives on sample size derivation for confirmatory trials

*The American Statistician* 2021; DOI:10.1080/00031305.2021.1901782

Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: A structured summary of a study protocol for a randomised controlled trial

*Trials* 2021; 22:270

Treatment allocation strategies for umbrella trials in the presence of multiple biomarkers: A comparison of methods

*Pharmaceutical Statistics* 2021; doi:10.1002/pst.2119

Statistical consideration when adding new arms to ongoing clinical trials: The potentials and the caveats

*Trials* 2021; 22:203

Mentalization for Offending Adult Males (MOAM): Study protocol for a randomized controlled trial to evaluate mentalization-based treatment for antisocial personality disorder in male offenders on community probation

*Trials* 2020; 21:1001

PSU4 Value of information for adaptive trials: Proof of concept study in multi-arm multi-stage trials of interventions for the prevention of surgical site infections

*Value in Health* 2020; 23(S2):S738